Please Subscribe to get a daily link to Pat's blog via email


Your privacy is important to us. We will never spam you and keep your personal data secure.

Monthly Archives: December 2012

10 12, 2012

BREAKING NEWS: Dr. Berenson’s Kyprolis results live up to the hype!

Tags: , , , , |6 Comments

Two weeks ago, Dr. Berenson hinted on our Myeloma Cure Panel broadcast that there were surprisingly hopeful numbers in a study he was conducting on relapsed/refractory patients.  This trial is one of the under the radar, good news stories from ASH. I couldn't release these results until 6 PM Eastern time today.  I have highlighted

10 12, 2012

MMRF ASH coverage and a heartfelt thank you!

Tags: , , , |8 Comments

My reporting from ASH tends to stress the human side of the meetings.  When I do report on specific presentations, I edit some of the information, only including what I think would be of interest to the majority of my readers. If you would like to know more, here is a link the the MMRF's

10 12, 2012

Reflections from a long Sunday at ASH – Part One

Tags: , , , , , , |1 Comment

I started the day listening to oral presentations about a number of experimental therapies.  No blockbuster news.  But I would be glad to share my thoughts. I’m not going to write about dosing data in any of these studies, even though dosing safety is the primary function of a Phase I/II study.  The good thing

9 12, 2012

Follow myeloma patient perspective blogs from ASH

Tags: , |0 Comments

The International Myeloma Foundation (IMF) is working with a group of support group leaders from across the country here at ASH--and I'm one of them!  Our mission is to use social media, blogging and video blogging to help communicate with other myeloma patients and caregivers.  The hope is that sharing what we learn from a

9 12, 2012

Interesting perspective about this week’s ASH meetings

Tags: |1 Comment

Read what hematology experts are saying about ASH this year: ASH: Seeking the Higher-Hanging Fruit By John Gever, Senior Editor, MedPage TODAY December 7th, 2012 ATLANTA -- New therapies for "hard-to-heal" hematologic disorders and strategies for reducing treatment-related toxicities without sacrificing efficacy will be major themes at the American Society of Hematology's annual meeting, top officials

8 12, 2012

Dr. Rajkumar still using incremental approach when treating newly diagnosed patients

Tags: , , , , , |4 Comments

Dr. Vincent Rajkumar is a magnificent speaker.  I have followed him giving presentations at ASH and ASCO for four years now.  He is more polished and forceful in his delivery these days.  His assertive confidence shines through. Dr. Rajkumar is not afraid to be a little bit different.  In the way Dr. Barlogie in Arkansas

7 12, 2012

Importance of accurate diagnostics and how to treat patients that cannot transplant

Tags: , , , , |2 Comments

In-between Dr. San-Miguel's smoldering myeloma presentation and Dr. Durie's presentation about treating patients that aren't stem cell transplant candidates, an animated, emotional exchange took place among panel participants. Specifically, Dr. San-Miguel strenuously objected to using X-rays alone to warn of possible bone involvement in smoldering myeloma patients.  He made the same point that I reported

7 12, 2012

To treat or not to treat smoldering myeloma

Tags: , , , , |0 Comments

There will be a lot of new information on MGUS and smoldering myeloma here at ASH this year. Dr. Jesus San-Miguel is kicking-things-off here right now, discussing the pros and cons of treating smoldering myeloma patients. In general, European studies show no advantage to treating smoldering patients early.  However, treating patients at highest risk of

7 12, 2012

High risk myeloma defined

Tags: , |15 Comments

Dr. Ola Landgren, a Senior Investigator for the National Cancer Institute (NCI), is speaking now. I will post a picture of Dr. Landgren later--I'm falling behind. Dr. Landgren's presentation went from dry to fascinating quickly.  It turns out that some of the indicators that specialists have been using to identify high risk patients Currently, there

7 12, 2012

Dr. Orlowski’s myeloma therapy overview

Tags: , , |2 Comments

Dr. Robert Orlowski is presenting his overview of the myeloma therapy landscape right now.  Sort of an overview of international treatment options. No new news so far.  This isn't surprising, considering his data does not include new things from these meetings. It was interesting to note that Thalomid maintenance therapy studies show a superior overall

7 12, 2012

IMF ASH Symposium Schedule

Tags: , |0 Comments

As we get ready to start, here is today's program schedule: 1:00 PM – 1:10 PM - Welcome and Introduction Program Director- Brian G.M. Durie, MD 1:10 PM – 1:40 PM - Overview of the Treatment Landscape in Myeloma Robert Z. Orlowski, MD, PhD 1:40 PM – 2:10 PM - Defining High-Risk Myeloma Ola Landgren,

7 12, 2012

Controversies in Multiple Myeloma IMF Symposium today in Atlanta

Tags: , , , , , , , |2 Comments

The IMF's annual Satellite Symposium kicks-off ASH each year.  This year's event is at the Georgia World Congress Center in Atlanta.  Pretty impressive place!  And very impressive agenda. Titled "Controversies in Multiple Myeloma: Current Debates in Optimal Care, the five hour event features a who's who of the international myeloma world.  Check-out the faculty list:

3 12, 2012

Another Patient Snapshot Update about John in Spokane

Tags: , |17 Comments

Myeloma survivor, John Knighten from Spokane, Washington, has been kind enough to email me weekly updates about his ongoing therapy.  John and his doctors in Seattle are preparing him for tandem auto/allo stem cell transplants after the first of next year. Not familiar with John's difficult myeloma journey?  This link to my post about him